News

Press Releases

• Mitsubishi Tanabe Pharma America Announces the Global Phase 3 Study of Oral Edaravone for ALS has Completed Enrollment

  ...

  Read more
  November 9, 2020
• Mitsubishi Tanabe Pharma America Celebrates ALS Caregiver & Screenwriter Featured In MDA Kevin Hart Kids Telethon

  ...

  Read more
  October 27, 2020
• Mitsubishi Tanabe Pharma America Announces Poster Presentation
  of ALS Data at American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2020 Meeting

  Post-Hoc Analysis of Phase 3 Study...

  Read more
  October 9, 2020
• Mitsubishi Tanabe Pharma America Announces Presentations at Northeast Amyotrophic Lateral Sclerosis 19th Annual Meeting

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  September 30, 2020
• Mitsubishi Tanabe Pharma America Announces Enrollment Has Resumed for the Global Phase 3 Study of Oral Edaravone for ALS

  JERSEY CITY, N.J., August 24, 2020 –...

  Read more
  August 24, 2020
• Mitsubishi Tanabe Pharma America Honors Third Anniversary of
  RADICAVA^® (Edaravone) in the U.S. & Company’s Support of ALS Community

  JERSEY CITY, N.J., August 6, 2020 –...

  Read more
  August 6, 2020
• Phase-3 Clinical Trial of MT-7117 Initiated in the U.S. for Rare Diseases, Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)

  MT-7117 Receives Orphan Drug Designation...

  Read more
  June 19, 2020
• Mitsubishi Tanabe Pharma America Announces Launch of the JourneyMate Program, Offering Live Nurse Educational Phone Support for ALS Patients and Caregivers

  JERSEY CITY, N.J., May 20, 2020 –...

  Read more
  May 20, 2020
• Mitsubishi Tanabe Pharma America Marks Third Anniversary of FDA Approval and Reports More Than 5,000 Patients with ALS Treated with RADICAVA^® (Edaravone)

  JERSEY CITY, N.J., May 5, 2020...

  Read more
  May 5, 2020
• New Post-Hoc Analysis of Phase 3 Study Examines Edaravone in ALS Patients with Bulbar and Limb Onset

  Data Presented at 2020 Muscular Dystrophy...

  Read more
  March 24, 2020
• MTPA’s Response to COVID-19

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  March 17, 2020
• Mitsubishi Tanabe Pharma America Celebrates Fourth Year in The U.S. Serving The ALS Community

  JERSEY CITY, N.J., February 7, 2020 –...

  Read more
  February 7, 2020
• Mitsubishi Tanabe Pharma America to Present Real-World Data on ALS Treatment at the 30th International Symposium on ALS/MND

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  December 4, 2019
• Mitsubishi Tanabe Pharma America to Spotlight Progress in ALS Research at 30th International Symposium on ALS/MND

  Presentations Include U.S. Real-World...

  Read more
  December 2, 2019
• Mitsubishi Tanabe Pharma America Announces Initiation of Phase 3 Study Evaluating Investigational Oral Formulation of Edaravone for ALS

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  November 25, 2019
• Mitsubishi Tanabe Pharma America to Receive Essey Commitment to Cures Award from the ALS Community for Extensive Efforts and Collaboration in ALS Research, Development and Education

  ALS Association Golden West Chapter Honors...

  Read more
  November 15, 2019
• First Patient Enrolled in MTPA REFINE-ALS Biomarker Study

  Study is Company’s First Clinical...

  Read more
  October 24, 2019
• Mitsubishi Tanabe Pharma America Announces Appointment of Gustavo A. Suarez Zambrano, M.D., as Vice President, Medical Affairs

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  September 26, 2019
• Mitsubishi Tanabe Pharma Corporation Group Announces Presentation of Patient- Reported Results from Phase 2 ND0612 Study at International Congress of Parkinson’s Disease and Movement Disorders

  Investigational Treatment with ND0612...

  Read more
  September 23, 2019
• Mitsubishi Tanabe Pharma America to Present on ALS Clinical Programs at 2019 Muscle Study Group Annual Scientific Meeting

  Company to Share Details on Collaboration...

  Read more
  September 20, 2019
• Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated in the United States for Parkinson’s Disease

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  August 28, 2019
• More Than 4,000 U.S. Patients with ALS Treated with RADICAVA^® (edaravone) in Two Years Since Availability, Mitsubishi Tanabe Pharma America Reports

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  August 8, 2019
• Mitsubishi Tanabe Pharma America Presents at 2019 National ALS Registry Annual Meeting in Atlanta

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  July 23, 2019
• MTPA Announces Nationwide Database of ALS Infusion Services to Help Patients and Caregivers Identify Local Providers

  Launch of Searchable Online Resource...

  Read more
  May 6, 2019
• Oxford Biodynamics Joins ALS Biomarker Study Sponsored by Mitsubishi Tanabe Pharma America

  Proprietary Technology Platform to Assess...

  Read more
  May 3, 2019
• Post-Hoc Analyses of ALS Treatment Studies Show Phase 3 Study Design Minimized ALS Heterogeneity to Improve Trial Efficiency

  Strategic Inclusion Criteria Enabled...

  Read more
  May 2, 2019
• Mitsubishi Tanabe Pharma America to Highlight ALS Research Initiatives at 2019 MDA Clinical & Scientific Conference

  Poster Presentations Include Real-World...

  Read more
  April 11, 2019
• Mitsubishi Tanabe Pharma America Announces Names of Teens And Young Adults Chosen for Inclusion In ALSO US™ Initiative

  Program Fosters Use of Original Written...

  Read more
  April 4, 2019
• Mitsubishi Tanabe Pharma America Announces Collaboration with Massachusetts General Hospital on ALS Biomarker Study

  Findings May Help Advance Understanding of...

  Read more
  March 28, 2019
• Mitsubishi Tanabe Pharma America Appoints Sam Shum as Vice President of Operations and Strategy

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  March 1, 2019
• Mitsubishi Tanabe Pharma America Accepting Independent Research Program Submissions for RADICAVA^® (edaravone) Through March 8

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  February 21, 2019
• Mitsubishi Tanabe Pharma America Announces More Than 3,500 ALS Patients in the U.S. Have Been Treated With RADICAVA^® (edaravone)

  Over 1,000 U.S. HCPs Have Prescribed...

  Read more
  February 6, 2019
• MTPA Launches National Online Directory of ALS Specialists and Neurologists at Multidisciplinary Centers

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  January 31, 2019
• Mitsubishi Tanabe Pharma America Announces Collaborative Study to Identify and Measure Biomarkers in People With ALS

  Findings Will Help Further Understanding...

  Read more
  December 6, 2018
• Mitsubishi Tanabe Pharma America to Showcase ALS Research at 29th International Symposium on ALS/MND in Glasgow

  Presentations Highlight Commitment to...

  Read more
  November 28, 2018
• Mitsubishi Tanabe Pharma Group Companies to Present New Data on Investigational Oral Formulation at MNDA

  Initial Study Results Show A Single Oral...

  Read more
  November 15, 2018
• Mitsubishi Tanabe Pharma America’s ALSO US^TM Initiative Begins Accepting Artistic Submissions from Teens Impacted by ALS

  Program to Showcase Original, Teen-Created...

  Read more
  November 5, 2018
• Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of ALS Treatment

  Mitsubishi Tanabe Pharma Canada, Inc....

  Read more
  October 4, 2018
• Mitsubishi Tanabe Pharma America Appoints Joseph Scalia As Vice President of Sales and Marketing

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  September 24, 2018
• Mitsubishi Tanabe Pharma America Announces over 3,000 Patients in the U.S. With ALS Have Been Treated With RADICAVA^® (Edaravone) in the Last Year

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  August 8, 2018
• Mitsubishi Tanabe Pharma America to Present Data on Radicava^® (Edaravone) at the European Network for the Cure of ALS (ENCALS) Annual Meeting

  Assessments of RADICAVA Clinical Trial...

  Read more
  June 21, 2018
• Mitsubishi Tanabe Pharma America Marks One-year Anniversary of Only FDA-approved ALS Treatment Option in the Last 20 Years

  Since Becoming Available, More Than 2,500...

  Read more
  May 7, 2018
• Mitsubishi Tanabe Pharma America and Neuroderm Announce Parkinson’s Disease Presentations at American Academy of Neurology Annual Meeting

  Phase 2 Data on Investigational...

  Read more
  April 18, 2018
• Mitsubishi Tanabe Pharma America Announces ALS Presentations at American Academy of Neurology Annual Meeting

  Analysis of Patient U.S. Health Claims...

  Read more
  April 18, 2018
• Health Canada Accepts Mitsubishi Tanabe Pharma Corporation’s NDS Filing for Edaravone to Treat ALS, Grants Priority Review

  Mitsubishi Tanabe Pharma Canada Launched...

  Read more
  April 9, 2018
• Mitsubishi Tanabe Pharma America Initiates Independent Research Program for RADICAVA^® (edaravone)

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  December 20, 2017
• Mitsubishi Tanabe Pharma America to Present Data on RADICAVA^® (Edaravone) At 28th International Symposium on ALS/MND in Boston

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  December 5, 2017
• Mitsubishi Tanabe Pharma America Announces Addition of RADICAVA^® (edaravone) to U.S. Department of Veterans Affairs National Formulary

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  November 30, 2017
• Mitsubishi Tanabe Pharma America Expands Executive Leadership Team, Names Kevin O’Brien as Vice President of Market Access

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  November 21, 2017
• Mitsubishi Tanabe Pharma America Announces 1,000 People with ALS Have Received FDA-Approved Treatment Option in First Three Months Available

  Searchlight Support^TM Staff...

  Read more
  November 16, 2017
• Comprehensive Edaravone Clinical Program Data Published as Supplement to Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  September 7, 2017
• Mitsubishi Tanabe Pharma America Signs Agreement with Option Care For National Home Infusion Services

  Mitsubishi Tanabe Pharma America, Inc....

  Read more
  September 6, 2017
• MTPA Perspective Regarding Medicare Coverage

  As an FDA-approved therapy, RADICAVATM...

  Read more
  August 9, 2017
• First FDA-approved Treatment for ALS in 22 Years Now Available in U.S.

  RADICAVA^TM (edaravone)...

  Read more
  August 8, 2017
• MT Pharma America Announces Corporate Name Change to Mitsubishi Tanabe Pharma America

  MT Pharma America, Inc. today announced...

  Read more
  August 1, 2017
• MT Pharma America Begins Patient Insurance Benefits Investigation Process in Advance of Availability of RADICAVA^TM (Edaravone)

  MT Pharma America, Inc. today announced...

  Read more
  July 25, 2017
• Mitsubishi Tanabe Pharma America Enrolls More Than 700 Sites of Care in Newly Created National Infusion Center Directory for ALS Patients

  MT Pharma America, Inc. today announced...

  Read more
  June 30, 2017
• Mitsubishi Tanabe Pharma America Presents 12-Month RADICAVA^TM (Edaravone) and Amyotrophic Lateral Sclerosis Data at the European Network for the Cure of ALS (ENCALS) Annual Meeting

  MT Pharma America, Inc. (MTPA) today...

  Read more
  May 18, 2017
• RADICAVA^TM (edaravone) Prescribing Information

  RADICAVA^TM (edaravone)...

  Read more
  May 5, 2017
• MT Pharma America Announces FDA Approval of RADICAVA^TM (Edaravone), the First New Treatment Option for ALS in More Than 20 Years

  First FDA-approved ALS treatment option in...

  Read more
  May 5, 2017
• MT Pharma America to Present Data on Investigational Edaravone and Amyotrophic Lateral Sclerosis at the 2017 American Academy of Neurology Annual Meeting

  MT Pharma America, Inc. (MTPA) today...

  Read more
  April 20, 2017
• 12-month Edaravone Clinical Study Data in ALS Presented at the 27th International Symposium on ALS/MND

  Mitsubishi Tanabe Pharma Corporation (Head...

  Read more
  December 9, 2016
• The ALS Association Welcomes MT Pharma America as National Corporate Sponsor

  The ALS Association is pleased to announce...

  Read more
  September 20, 2016
• FDA Accepts Mitsubishi Tanabe Pharma’s NDA Filing for Edaravone to Treat ALS

  Edaravone may be the first ALS treatment...

  Read more
  August 30, 2016
• Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United States

  Mitsubishi Tanabe Pharma Corporation...

  Read more
  June 20, 2016
• Mitsubishi Tanabe Pharma Corporation Presents Edaravone Clinical Trial Data in ALS at 2016 American Academy of Neurology Annual Meeting

  Mitsubishi Tanabe Pharma Corporation...

  Read more
  April 20, 2016

Load More